Its role Owner
Neolpharma, S.A. de C.V., operating as Grupo Neolpharma, is a privately held Mexican pharmaceutical group with 100% domestic capital. It specializes in the research, development, production, commercialization, and distribution of pharmaceutical products, focusing on affordable, high-quality medicines for various therapeutic areas including neuroscience, oncology, cardiovascular conditions, infectious diseases, and analgesics.
The group comprises multiple independent legal entities and operates several manufacturing facilities across Mexico. Key sites include advanced plants in the Vallejo industrial area of Mexico City for solid, liquid, injectable, and other dosage forms with decades of experience; the NeolSyM multipurpose API production plant in Ecatepec, Estado de México; and recently acquired API facilities in Toluca (Signa plant from Apotex) and Morelos. It also maintains a production site in Caguas, Puerto Rico, to facilitate exports primarily to the United States and other markets.
Neolpharma emphasizes vertical integration by expanding local API manufacturing to decrease Mexico's heavy reliance on imported active pharmaceutical ingredients. The company has a portfolio exceeding 200 registered products and provides services in drug development and manufacturing. It has undertaken significant investments, including acquisitions and expansions supported by international financing such as from the IFC, aiming to create jobs, enhance supply chain resilience, and support exports to regulated markets like the US, Europe, Japan, and Canada.
As one of Mexico's prominent pharmaceutical players, the group contributes to national self-sufficiency in medicines and participates in initiatives aligned with industrial development plans.
Also known as Neolpharma SA de CV, NeolSyM, Psicofarma, and Alpharma.
chemXplore tracks 3 projects involving Neolpharma, of which 3 are active.
Closest to start-up first.
active all projects
